Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.HBI sells OTC firm Antula to Meda
Antula Healthcare, an independent over-the-counter (OTC) healthcare company in the Nordic markets, is the wholly owned Swedish subsidiary of HBI. The sale to Meda will allow HBI to
Antula Healthcare, an independent over-the-counter (OTC) healthcare company in the Nordic markets, is the wholly owned Swedish subsidiary of HBI. The sale to Meda will allow HBI to
Under the agreement, Beactica will use its proprietary drug discovery platform, Sprint, to generate small-molecule lead compounds against undisclosed targets of therapeutic interest to Janssen. Reportedly, Janssen is
The expansion of the trial (currently ongoing in France) to two new countries will raise the total number of centers to over 40 and will help accelerate patient
CCR4 is one of 18 known chemokine receptors – proteins which bind molecules called chemokines to trigger various cellular responses. Developing antibodies to interfere with CCR4-expressing cells, such
Germany-based Huttlin produces specialist drying and granulation equipment from powder to the production of pharmaceuticals. The UK based Manesty specializes in tablet presses and coaters. Bosch Packaging Technology,
Impax, a manufacturer of both brand and generic drug products, has implemented SAP to derive the benefits of tighter integration of global processes, accelerate the adoption of best
The analysis evaluated data from two large multinational Phase III, double-blind, placebo-controlled studies (RAPID 1 and 2) comparing the efficacy and safety of certolizumab pegol plus MTX versus
The new patent entitled, ‘Methods for Treating Disorders or Diseases Associated with Hyperlipidemia and Hypercholesterolemia While Minimizing Side Effects,’ relates to step-wise increase of lomitapide doses for the
PPD has posted a net income of $37.37m, or $0.32 per diluted share, compared to $17.2m, or $0.14 per diluted share, for the same period in 2010. For
IQ Therapeutics said doses up to 7.5 mg/kg have been administered, as per protocol. IQNLF is a fully human antibody developed using IQ Therapeutics’ proprietary technology – Cloning